sofidexFor patientsAre you a clinician? Clinical site
Ask Sofi
Listen
Patient SupportEmergencies & Reporting
Log inSign up

Meds & supplements  ›  Alpelisib

Medicine

Alpelisib

VIJOICE is indicated for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for
  • This indication is approved under accelerated approval based on response rate and duration of response.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
  • VIJOICE is a kinase inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy.
Do not take if
PIQRAY is contraindicated in patients with severe hypersensitivity to it or any of its components.

What it is used for

PIQRAY is indicated in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.

Side effects, and when to stop

The following adverse reactions are discussed in greater detail in other sections of the labeling:

  • Severe Hypersensitivity
  • Severe Cutaneous Adverse Reactions
  • Hyperglycemia
  • Pneumonitis
  • Diarrhea or Colitis

Who should not take it

PIQRAY is contraindicated in patients with severe hypersensitivity to it or any of its components.

Cite this page

NLM

sofidex [Internet]. Daloreum; c2026. Alpelisib; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/alpelisib

APA 7th

sofidex. (2026, August 2). Alpelisib. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/alpelisib

AMA 11th

Alpelisib. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/alpelisib

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.